The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

The Senate has confirmed Dr Jay Bhattacharya as the new director of the NIH and Dr Marty Makary as the new commissioner of the FDA.

Cretostimogene is an oncolytic immunotherapy with dual mechanism of action: viral replication leading to tumor lysis and release of granulocyte-macrophage colony stimulating factor.

Maintaining systolic blood pressure consistently below 130 mmHg could help decrease the risk for new-onset diabetes in the ...

More than 2 decades have passed since I became the first full-time editor of Renal & Urology News. During that time, the ...

Durvalumab plus gemcitabine and cisplatin significantly improved event free survival and overall survival compared with gemcitabine and cisplatin. The Food and Drug Administration (FDA) has ...

Although the role of radiation therapy is well established in this setting, the role of radical prostatectomy in treating men with de novo oligometastatic prostate cancer has not been well defined.

A Chinese woman is the third person in the world living with a gene-edited pig kidney, and nearly 3 weeks after surgery, doctors say she’s doing well. The woman, reportedly 69 years old, had kidney ...

The presence of residual tumor cells in the trigone and urethra after robot-assisted radical cystectomy (RARC) is associated with a higher tumor stage, positive margins, and cancer recurrence compared ...

A trial tested MRI and microultrasonography guided biopsy separately and in combination for the detection of clinically significant prostate cancer.